Headlines about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have been trending positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned a daily sentiment score of 0.29 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.6024995724821 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

A number of equities analysts have commented on the stock. Maxim Group set a $8.00 target price on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 13th. ValuEngine downgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, July 14th.

Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) traded up 0.48% during trading on Monday, reaching $4.20. 28,418 shares of the company’s stock were exchanged. The stock’s market capitalization is $78.69 million. Brainstorm Cell Therapeutics has a 52 week low of $2.06 and a 52 week high of $5.18. The stock has a 50 day moving average price of $4.45 and a 200-day moving average price of $4.05.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/brainstorm-cell-therapeutics-nasdaqbcli-receives-coverage-optimism-rating-of-0-29/1486780.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Insider Buying and Selling by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.